Supplemental Figure 1 from Cytogenetic and Molecular Associations with Outcomes in Higher-Risk Myelodysplastic Syndromes Treated with Hypomethylating Agents plus Venetoclax | Synapse
April 1, 2024Open Access
Supplemental Figure 1 from Cytogenetic and Molecular Associations with Outcomes in Higher-Risk Myelodysplastic Syndromes Treated with Hypomethylating Agents plus Venetoclax
Puntos clave
Los puntos clave no están disponibles para este artículo en este momento.
Resumen
Supplemental Figure 1: Overall survival and event-free survival in HMA-naïve patients by response.